256 related articles for article (PubMed ID: 33976037)
41. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
42. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
[TBL] [Abstract][Full Text] [Related]
43. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
44. Antrodia cinnamomea is a potentially effective complementary medicine for adjuvant therapy against breast cancer with bone metastasis: A case report.
Long H; Hu CT; Prijatelj V; Weng CF
Medicine (Baltimore); 2020 Jul; 99(27):e20808. PubMed ID: 32629666
[TBL] [Abstract][Full Text] [Related]
45. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Goetz MP; Toi M; Campone M; Sohn J; Paluch-Shimon S; Huober J; Park IH; Trédan O; Chen SC; Manso L; Freedman OC; Garnica Jaliffe G; Forrester T; Frenzel M; Barriga S; Smith IC; Bourayou N; Di Leo A
J Clin Oncol; 2017 Nov; 35(32):3638-3646. PubMed ID: 28968163
[TBL] [Abstract][Full Text] [Related]
46. Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature.
Gao HF; Zhang JS; Zhang QZ; Zhu T; Yang CQ; Zhang LL; Yang M; Ji F; Li JQ; Cheng MY; Niu G; Wang K
Front Endocrinol (Lausanne); 2021; 12():659537. PubMed ID: 34690920
[TBL] [Abstract][Full Text] [Related]
47. [Palbociclib combinations as new therapeutic strategies in the treatment of HR+/HER2- advanced breast cancer].
Boér K
Magy Onkol; 2017 Jun; 61(2):167-173. PubMed ID: 28585619
[TBL] [Abstract][Full Text] [Related]
48. [Locally Advanced Breast Cancer Successfully Treated with Abemaciclib and Fulvestrant-A Case Report].
Matsushita K; Hagihara K; Motoki Y; Sakisaka H; Akiyama Y; Nakaguchi K; Doi S
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2165-2167. PubMed ID: 33468895
[TBL] [Abstract][Full Text] [Related]
49. Abemaciclib and Fulvestrant for Bilateral Choroidal Metastasis From Breast Carcinoma.
Barke MR; Agrawal KU; Shields CL
JAMA Ophthalmol; 2022 Oct; 140(10):1026-1028. PubMed ID: 36074499
[TBL] [Abstract][Full Text] [Related]
50. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Goetz MP; Okera M; Wildiers H; Campone M; Grischke EM; Manso L; André VAM; Chouaki N; San Antonio B; Toi M; Sledge GW
Breast Cancer Res Treat; 2021 Apr; 186(2):417-428. PubMed ID: 33392835
[TBL] [Abstract][Full Text] [Related]
52. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer.
Cuyun Carter G; Sheffield KM; Gossai A; Huang YJ; Zhu YE; Bowman L; Nash Smyth E; Mathur R; Cohen AB; Rasmussen E; Balakrishna S; Morato Guimaraes C; Rybowski S; Seidman AD
Curr Med Res Opin; 2021 Jul; 37(7):1179-1187. PubMed ID: 33970738
[TBL] [Abstract][Full Text] [Related]
53. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
54. Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients.
Herrscher H; Velten M; Leblanc J; Kalish-Weindling M; Fischbach C; Exinger D; Pivot X; Petit T
Breast Cancer Res Treat; 2020 Jan; 179(2):371-376. PubMed ID: 31612291
[TBL] [Abstract][Full Text] [Related]
55. Palbociclib Plus Fulvestrant Maintains Long-Term Overall Survival Benefit in HR+/HER2- Advanced Breast Cancer.
Oncologist; 2021 Jul; 26 Suppl 3(Suppl 3):S5-S6. PubMed ID: 34152059
[TBL] [Abstract][Full Text] [Related]
56. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
57. Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points.
Law E; Gavanji R; Walsh S; Haltner A; McTavish R; Cameron C
J Comp Eff Res; 2022 Feb; 11(2):109-120. PubMed ID: 34751591
[No Abstract] [Full Text] [Related]
58. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
59. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
60. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Varella L; Eziokwu AS; Jia X; Kruse M; Moore HCF; Budd GT; Abraham J; Montero AJ
Breast Cancer Res Treat; 2019 Jul; 176(2):429-434. PubMed ID: 30895534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
